medigraphic.com
ISSN 2500-7106 (Electronic)
ISSN 0123-2576 (Print)
Medicina & Laboratorio

2022, Number 4

Next >>

Medicina & Laboratorio 2022; 26 (4)

From messenger RNA to viral vectors and recombinant proteins: the evolution of vaccines against COVID-19

Díaz-Castrillón FJ, Toro-Montoya AI

Language: Spanish
References: 21
Page: 319-322
PDF size: 55.64 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Thanh-Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, et al. TheCOVID-19 vaccine development landscape. Nat Rev Drug Discov 2020;19:305-306. https://doi.org/10.1038/d41573-020-00073-5.

  2. Zhao J, Zhao S, Ou J, Zhang J, Lan W, Guan W, et al. COVID-19: Coronavirus vaccine developmentupdates. Front Immunol 2020;11:602256. https://doi.org/10.3389/fimmu.2020.602256.

  3. World Health Organization (WHO). WHO coronavirus (COVID-19) dashboard with vaccination data.Ginebra, Suiza: WHO; 2022. Acceso 7 de septiembre de 2022. Disponible en https://covid19.who.int/.

  4. Centers for Disease Control and Prevention (CDC). COVID Data Tracker. COVID-19 vaccine effectivenessmonthly update. Atlanta, GA: US Department of Health and Human Services, CDC; 2022. Acceso 7 deseptiembre de 2022.Disponible en https://covid.cdc.gov/covid-data-tracker/#vaccine-effectiveness.

  5. Bouland AJ, March JA. Invited Editorial: Characteristics and outcomes of adverse events following COVID-19 vaccination. J Am Coll Emerg Physicians Open 2021;2:e12566. https://doi.org/10.1002/emp2.12566.

  6. U.S. Food and Drug Administration (FDA). FDA takes key action in fight against COVID-19 by issuing emergencyuse authorization for first COVID-19 vaccine. Maryland, Estados Unidos: 2020. Acceso 7 de septiembrede 2022. Disponible en https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fightagainst-covid-19-issuing-emergency-use-authorization-first-covid-19.

  7. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of theBNT162b2 mRNA COVID-19 vaccine. N Engl J Med 2020;383:2603-2615. https://doi.org/10.1056/NEJMoa2034577.

  8. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of themRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384:403-416. https://doi.org/10.1056/NEJMoa2035389.

  9. U.S. Food and Drug Administration (FDA). FDA issues emergency use authorization for third COVID-19 vaccine.Maryland, Estados Unidos: FDA; 2021. Acceso 7 de septiembre de 2022. Disponible en https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-third-covid-19-vaccine.

  10. The New York Times. Tracking coronavirus vaccinations around the world. New York, Estados Unidos: TheNew York Times; 2022. Acceso 7 de septiembre de 2022. Disponible en https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html.

  11. Vanaparthy R, Mohan G, Vasireddy D, Atluri P. Review of COVID-19 viral vector-based vaccines andCOVID-19 variants. Infez Med 2021;29:328-338. https://doi.org/10.53854/liim-2903-3.

  12. U.S. Food and Drug Administration (FDA). Coronavirus (COVID-19) update: FDA authorizes emergency useof Novavax COVID-19 vaccine, adjuvanted. Maryland, Estados Unidos: FDA; 2022. Acceso 7 de septiembre de2022. Disponible en https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-updatefda-authorizes-emergency-use-novavax-covid-19-vaccine-adjuvanted.

  13. Ministerio de Salud y Protección Social (Minsalud). Vacunación contra COVID-19. Bogotá, Colombia:Minsalud; 2022. Acceso 7 de septiembre de 2022. Disponible en https://www.minsalud.gov.co/salud/publica/Vacunacion/Paginas/Vacunacion-covid-19.aspx.

  14. Mistry P, Barmania F, Mellet J, Peta K, Strydom A, Viljoen IM, et al. SARS-CoV-2 variants, vaccines,and host immunity. Front Immunol 2021;12:809244. https://doi.org/10.3389/fimmu.2021.809244.

  15. Tang J, Zeng C, Cox TM, Li C, Son YM, Cheon IS, et al. Respiratory mucosal immunity againstSARS-CoV-2 following mRNA vaccination. Sci Immunol 2022:eadd4853. https://doi.org/10.1126/sciimmunol.add4853.

  16. U.S. Food and Drug Administration (FDA). Coronavirus (COVID-19) update: FDA recommends inclusion ofOmicron BA.4/5 component for COVID-19 vaccine booster doses. Maryland, Estados Unidos: FDA; 2022. Acceso7 de septiembre de 2022. Disponible en https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-recommends-inclusion-omicron-ba45-component-covid-19-vaccine-booster.

  17. U.S. Food and Drug Administration (FDA). Coronavirus (COVID-19) update: FDA authorizes Moderna, Pfizer-BioNTech bivalent COVID-19 vaccines for use as a booster dose. Maryland, Estados Unidos: FDA; 2022. Acceso7 de septiembre de 2022. Disponible en https://www.fda.gov/news-events/press-announcements/coronaviruscovid-19-update-fda-authorizes-moderna-pfizer-biontech-bivalent-covid-19-vaccines-use.

  18. U.S. Food and Drug Administration (FDA). Joint CDC and FDA statement on Johnson & Johnson COVID-19vaccine. Maryland, Estados Unidos: FDA; 2021. Acceso 7 de septiembre de 2022. Disponible en https://www.fda.gov/news-events/press-announcements/joint-cdc-and-fda-statement-johnson-johnson-covid-19-vaccine.

  19. U.S. Food and Drug Administration (FDA). Coronavirus (COVID-19) update: December 14, 2021. Maryland,Estados Unidos: FDA; 2021. Acceso 7 de septiembre de 2022. Disponible en https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-december-14-2021.

  20. U.S. Food and Drug Administration (FDA). Coronavirus (COVID-19) update: June 25, 2021. Maryland, EstadosUnidos: FDA; 2021. Acceso 7 de septiembre de 2022. Disponible en https://www.fda.gov/news-events/pressannouncements/coronavirus-covid-19-update-june-25-2021.

  21. U.S. Food and Drug Administration (FDA). Coronavirus (COVID-19) update: August 3, 2021. Maryland, EstadosUnidos: FDA; 2021. Acceso 7 de septiembre de 2022. Disponible en https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-august-3-2021.




2020     |     www.medigraphic.com